## **510(K) SUMMARY**

## **UC-CARE** Warming System

AUG 1 0 2009

# 510(k) Number K 090918

Applicant's Name: UC-CARE, Ltd.

New Ind. Zone, Apollo Bldg.

P.O.Box 67 Yokneam 20692

Tel: (972)4-909-7427 Fax: (972)4-993-7323

Contact Person: Roni Zvuloni, Ph.D.

CTO

UC-CARE, Ltd.

New Ind. Zone, Apollo Bldg.

P.O.Box 67 Yokneam 20692 Tel: (972)4-909-7427 Fax: (972)4-993-7323

Fax: (9/2)4-993-/32

Trade Name: UC-CARE Warming System (UCW System)

Classification: Name: Unit, Cryosurgical, Accessories Product Code: GEH

Regulation No: CFR 21 878.4350

Class: II

Panel: General & Plastic Surgery

#### **Device Description:**

The UCW System is indicated to transfer heat to the urethral tissue during urological cryosurgical procedures of the prostate. The UCW System includes a Urethral Catheter & Tubing Set and a Warming Kt

The Urethral Catheter is introduced into the bladder to outline the urethral course, and to protect the urethral during therapeutic transperineal, prostatic cryotherapy procedures. The Urethral catheter further transfers heat to the urethral tissue during cryotherapy of the prostate in order to protect the urethral from excessive cold temperatures. The closed loop Tubing Set is connected to the catheter's inlet and outlet ports and circulates warm sterile water or saline via the Warming Kit that includes a fluid warmer and peristaltic pump.

#### **Intended Use Statement:**

The UC-CARE Warming System is indicated to transfer heat to the urethral tissue during urological cryosurgical procedures of the prostate using cryosurgical systems that have been cleared for use on the prostate.

**Predicate Devices**: Substantial equivalence to the following predicate device is claimed:

Device Name	510k No	Date of approval
Endocare Urethral Warming System (Endocare Inc.)	K963970	997125 Feb,
SEEDNET, SEEDNET GOLD, CRYOHIT, CRYO THERA, (PresIce <sup>TM</sup> )	K060390	27 Apr, 2006

#### **Performance Standards:**

The UC-Care Warming System has been tested according to various standards and guidance documents, like the ASTM F623-99 (2006) – Standard Performance Specification for Foley Catheter.

### Substantial Equivalence:

The UC Care Warming System is as safe and effective as the Endocase Urethral Warming System and the Galil Medical Seednet device. The UC Care Warming System has the same intended uses and similar indications, technological characteristics, and principles of operation as its predicate devices. Any technological differences between the device and its predicate devices raise no new issues of safety or effectiveness. Performance data demonstrate that the UC Care Warming Device is as safe and effective as the predicate devices. Thus, the UC Care Warming Device is substantially equivalent.

#### Conclusion:

UC-CARE Ltd. believes that, based on the information provided in this submission, the UC-Care Warming System is substantially equivalent to its predicate devices without raising any new safety and/or effectiveness concerns.



Food and Drug Administration 10903 New Hampshire Avenue

Document Control Room – WO66-G609 Silver Spring, MD 20993-0002

UC CARE, Ltd. % Mr. Jonathan S. Kahan Partner Hogan & Hartson, LLP Columbia Square 555 Thirteenth Street, N.W. WASHINGTON DC 20004

AUG 1 0 2009

Re: K090978

Trade/Device Name: UC CARE Warming System

Regulation Number: 21 CFR 878.4350

Regulation Name: Cryosurgical unit and accessories

Regulatory Class: II

Product Code: GEH and EZL

Dated: August 3, 2009 Received: August 5, 2009

Dear Mr. Kahan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <a href="http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm">http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm</a> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <a href="http://www.fda.gov/cdrh/mdr/">http://www.fda.gov/cdrh/mdr/</a> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely yours,

Janine M. Morris

Acting Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

## **Indications for Use Statement**

510(k) Number (if known):	K090978		
Device Name:	UC CARE Warming System		
Indications for Use:	The UC-CARE Warming System is indicated to transfer heat to the urethral tissue during urological cryosurgical procedures of the prostate using cryosurgical systems that have been cleared for use on the prostate.		
Prescription Use X (Part 21 CFR 801 Subpart D)	_ AND/OR	Over-The-Counter Use (21 CFR 801 Subpart C)	
(PLEASE DO NOT WRITE IF NEEDED)	E BELOW THIS LINE	-CONTINUE ON ANOTHER PAGE	
Concurrence of CDRH, Offi	ce of Device Evaluation	n (ODE)	
(Division Sign-off) Division of General & Plasti 510(k) Number	c Surgery Devices		

(Division Sign-Off)
Division of Reproductive, Abdominal, and Radiological Devices

510(k) Number\_\_\_\_\_\_